A simmering disgust over the price of Mylan’s EpiPens boiled over on Capitol Hill Wednesday as Democratic and Republican lawmakers slammed the drug maker for taking advantage of its monopoly on the emergency allergy treatment at the expense of middle-class Americans, jacking up the price to fuel “exorbitant profits” and awarding its top executives out-sized pay.

“You raised the price to get filthy rich at the expense of our constituents,” said Rep. Elijah Cummings, D-Md., during a House Oversight Committee hearing triggered by a widening outcry over the auto-injector’s cost, which has soared from $100 for a two-pack to over $600 in recent years.

“You used a simple but corrupt business model that other drug companies have repeatedly used: Find an old, cheap drug that has virtually no competition and raise the price over and over again as high as you can,” Mr. Cummings told the company’s CEO, Heather Bresch.

As she has in the past, Ms. Bresch said Mylan had worked hard to make the EpiPen available to more people, including giving some 700,000 of the devices away to schools.

Advertise with us

She also said the company doesn’t make as much profit on EpiPens as many believe.

“I think many people incorrectly assume we make $600 off each EpiPen. It’s simply not true,” she testified, saying that Mylan’s profit was about $100 a pack, after costs, fees and rebates.

Several committee members asked Ms. Bresch to explain her nearly $19 million pay package last year, and whether meeting compensation targets was a motivation for raising the price of the EpiPen, which accounts for roughly 10 percent of the company’s revenue.

“No,” Ms. Bresch replied. “EpiPen is a factor in Mylan’s overall performance.”

Lawmakers weren’t sympathetic.

Advertise with us

“The greed is astounding. It’s sickening,” Rep. Jimmy Duncan, R-Tenn., offered. “Not only by Ms. Bresch, but by the other executives [at Mylan].”

The ire in the room wasn’t focused solely on Mylan. Lawmakers also blasted the Food and Drug Administration for playing a role in escalating prescription drug prices nationwide by taking too long to approve drug applications, stifling competition in the marketplace.

“The FDA needs to speed up its actions,” Rep. Duncan told Douglas Throckmorton, the agency’s deputy director for the Center for Drug Evaluation and Research.

“We’ve let [the FDA] become so big and bureaucratic, it’s almost impossible for a company to get a drug or medical device to market.”

Besides the controversy over the EpiPen, Ms. Bresch drew fire on a number of other fronts, including the Cecil-based company’s reincorporation in the Netherlands to lower its tax bill. She also faced questions about what role her mother, Gayle Manchin, wife of U.S. Sen. Joe Manchin, D-W.Va., played in promoting the EpiPen while serving as president of the National Association of State Boards of Education.

Advertise with us

“My mother ... rotated one year into the president’s [position] in 2012 then rotated out,” Ms. Bresch testified.

“I thought it was a cheap shot to bring my mother into this,” she said of media reports questioning Mrs. Manchin’s influence.

Mr. Cummings said he was concerned that Mylan executives were using a typical “rope-a-dope strategy” to wait out the current storm over the EpiPen, then resume raising prices.

“After Mylan takes our punches, they’ll fly back to their mansions on their private jets and laugh all way to the bank,” he said.

“It’s time for Congress to act” to bring down the cost of prescription drugs, he said. “I beg all of our colleagues to take this moment. This is our moment.”

Advertise with us

Despite the grilling, Ms. Bresch gave no indication she planned to lower the cost of the EpiPen. She reiterated that Mylan had answered the furor by expanding its prescription assistance program and by announcing plans to introduce a half-price generic auto-injector identical to the EpiPen —-- moves one lawmaker referred to as “a shell game” by big pharmaceutical companies that keeps drug prices high by shifting costs to insurers.

Rep. Mick Mulvaney, R-S.C., told Ms. Bresch that the recent attention on Mylan and its EpiPen profits by government officials and lawmakers — including inquiries in the Senate and investigations by the attorneys general of New York and West Virginia —-- meant the company was getting what it deserved.

“You’ve been in these hallways to ask us to make people buy your stuff,” Mr. Mulvaney said, referring to laws in many states that require schools to have EpiPens on hand.

“You asked the government to get into your business. So here we are today.

“If you want to come into Washington and lobby us to make us buy your stuff, this is what you get — a level of scrutiny and treatment that would curl my hair. But you asked for it.”

Advertise with us

The afternoon hearing, which extended into the evening, came a day after West Virginia’s attorney general disclosed an investigation of whether Mylan violated antitrust laws or defrauded the state’s Medicaid program by shortchanging the government on EpiPen rebates.

Also this week, the U.S. Senate Finance Committee asked the Department of Health and Human Services to investigate the oversight of the Medicaid rebate system.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.